Akzo Nobel - Pharma Prospects to 2010

Table of Contents

• Principal Operating Results
• Latest Results

EXECUTIVE SUMMARY

• Introduction
  • Current Growth Drivers
  • Key Late-Stage Products
  • Key Early-Stage Products
• Financial Performance 2005
  • Sales and Market Position
  • Income
    • Operating Income (Loss) By Business Area
    • Operating Income (Loss) By Geographical Area
  • Expenditure
    • Capital Expenditure
    • Capital Expenditure By Business Area
    • Invested Capital By Business Area
    • Capital Expenditure By Geographical Area
    • Invested Capital By Geographical Area
    • R&D Expenditure
    • R&D Expenditure By Business Area
  • Divisional Performance
    • Sales By Business Area
    • Breakdown Of Pharma Sales By Business Unit
    • Total Assets By Business Area
  • Geographic Performance
    • Sales By Destination
    • Sales By Origin
    • Total Assets By Geographical Area
    • Breakdown Of Organon Sales By Destination
• Company Strategy
  • Mergers, Acquisitions and Divestitures
    • Acquisitions
    • Divestitures
  • Key Agreements
• Discontinued Agreements
  • Production
  • Employees
    • Employees By Business Area (Average)
    • Employees By Geographical Area (Year End)
• Product / R&D Overview
  • Key Products
    • Recent Product Launches
    • Recent Product Approvals
  • R&D Strategy
    • Key R&D Projects
  • R&D Pipeline Overview
    • Discontinued R&D projects
    • Variza
    • Org 41793 (DPI 3290)
  • Sales Forecasts
• Conclusions/Outlook

PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT

• Breakdown By Therapeutic Area/Major Products
  • R&D Pipeline
• Contraception - Products
  • Cerazette
    • Mode of Action
    • Key Markets/Indications
    • Clinical Trial Results
  • Implanon
    • Mode of Action
    • Sales
    • Key Markets/Indications
    • Sales Forecast
  • NuvaRing
    • Mode of Action
    • Sales
    • Key Markets/Indications
    • Clinical Trial Results
  • Others
• Contraception - R&D
  • Clira
  • EMM 310066
  • Org 3236
  • Org 39970
  • Org 41749
  • Org 42152
  • Org 42669
  • Org 43228
  • Org 43979
  • Org 45414
  • Org 50081
• Contraception - Summary
  • Growth Potential
• Fertility - Products
  • Follegon
  • Humegon
  • Normegon
  • Orgalutran/Antagon
    • Key Markets/Indications
  • Puregon/Follistim
    • Mode of Action
    • Sales
    • Key Markets/Indications
    • Competitor Products
    • Sales Forecast
• Fertility - R&D
  • Corifollitropin alpha
    • Mode of Action
  • Clinical Trial Results
• Fertility - Summary
  • Growth Potential
• Menopausal Complaints - Products
  • Divina/Dilena
  • Divitren
  • Livial/Xyvion/Liviella
    • Mode of Action
    • Sales
    • Key Markets/Indications
    • Further Development
    • Sales Forecast
    • Clinical Trial Results
  • Riselle
  • Sandrena
• Menopausal Complaints - R&D
  • Liseta
• Menopausal Complaints - Summary
  • Growth Potential
  • Limiting Factors
• Other Reproductive - Products
  • Andriol
  • Cerviprost
  • GynoLomexin
  • Others
• Central Nervous System - Products
  • Remeron
    • Mode of Action
    • Sales
    • Key Markets/Indications
    • Patents
    • Competitor Products
    • Generic Competition/Lawsuits
    • Sales Forecast
    • Clinical Trials Results - Remeron SolTab
  • Tecipul
  • Terranas
  • Tolvon
• Anaesthesia - Products
  • Arduan
  • Esmeron/Zemuron
  • Norcuron
  • Pavulon
• Central Nervous System - R&D
  • Asenapine (Org 5222)
    • Mode of Action
  • Farampator (Org 24448)
    • Mode of Action
    • Clinical Trial Results
  • Org 207788/Org 26828/Org 28611
  • Org 25935/Org 26041
  • Org 26576
  • Org 34167
  • Org 34517
  • Org 4419
  • Org 50189
  • Sugammadex (Org 25969)
    • Mode of Action
    • Development Status
    • Clinical Trial Results
• Central Nervous System - Summary
  • Growth Potential
  • Limiting Factors
• Cardiovascular - Products
  • Bepricor/Cordium/Vascor
  • Orgaran
• Cardiovascular - R&D
  • Org 42675
• Cancer - Products
  • OncoTICE/TiceBCG
• Cancer - R&D
  • SOT-375
• Cancer - Summary
• Other - Products
  • Rimexel

APPENDIX 1 - FINANCIAL PERFORMANCE

• Full Year Results 2005

APPENDIX 2 - KEY AGREEMENTS

• Barr Pharmaceuticals Inc/Savient Pharmaceuticals Inc
  • November 1990
  • 12th January 1999
  • 8th September 2005
  • 2nd December 2005
• BioDiem Ltd
  • 24th November 2004
• BrainCells Inc
  • 23rd October 2006
• Cortex Pharmaceuticals Inc
  • January 1999
  • 30th January 2001
• Cypress Bioscience Inc
  • 29th June 2005
  • 27th June 2006
• Dendreon Corporation
  • 2nd March 2006
• Entelos Inc
  • 24th April 2002
  • 15th February 2005
• Gene Logic Inc
  • 21st April 2006
• Gene Networks International (GNI)
  • 24th January 2006
• HD Biosciences
  • 17th November 2005
• Keel Pharmaceuticals Inc
  • 21st November 2005
• KineMed Inc
  • 29th June 2006
• Laboratoire Theramex
  • 31st June 2005
• Lexicon Genetics Incorporated
  • 26th July 2001
  • 17th June 2005
• Medarex Inc
  • 1st February 2006
• Meiji Seika Kaisha Ltd
  • 5th August 2004
• Netherlands Vaccine Institute (NVI)
  • 6th July 2006
• Pfizer
  • 2nd June 2003
  • 20th October 2003
  • 24th December 2003
• Pharmacopeia Inc
  • June 1997
  • 19th October 1999
  • 24th January 2000
  • 10th July 2000
  • 11th January 2001
  • 13th February 2002
  • 30th August 2005
  • 11th January 2006
  • 19th September 2006
• Roche
  • Orgalutran agreement
  • 7th February 1996
  • Serotonin receptor ligands agreement
• sanofi-aventis
  • 1st January 2006
  • 7th January 2004
• Sosei Co Ltd
  • 16th December 2003
• Others

APPENDIX 3 - INFRASTRUCTURE

• Research & Development Facilities
• Manufacturing Facilities

APPENDIX 4 - KEY PHARMACEUTICAL SUBSIDIARIES / JOINT VENTURES

• Subsidiaries
• Pharma Group Business Units and Subsidiaries
• Joint Ventures

APPENDIX 5 - PRODUCT INDEX

INDEX OF TABLES

• Principal Operating Results
• Operating Income (Loss) By Business Area
• Operating Income (Loss) By Geographical Area
• Capital Expenditure By Business Area
• Invested Capital By Business Area
• Capital Expenditure By Geographical Area
• Invested Capital By Geographical Area
• R&D Expenditure By Business Area
• Sales By Business Area
• Breakdown Of Pharma Sales By Business Unit
• Total Assets By Business Area
• Sales By Destination
• Sales By Origin
• Total Assets By Geographical Area
• Breakdown Of Organon Sales By Destination
• Employees By Business Area (Average)
• Employees By Geographical Area (Year End)
• Recent Product Launches
• Recent Product Approvals
• Key R&D Projects
• Breakdown By Therapeutic Area/Major Products
• R&D Pipeline

INDEX OF CHARTS

• Sales, Costs and Operating Income
• Operating Income (Loss) By Business Area
• Operating Income (Loss) By Geographical Area
• R&D Expenditure and Capital Expenditure
• Capital Expenditure By Business Area, 2005
• Invested Capital By Business Area, 2005
• Capital Expenditure By Geographical Area, 2005
• Invested Capital By Geographical Area, 2005
• R&D Expenditure By Business Area
• Sales By Business Area
• Breakdown Of Pharma Sales By Business Unit, 2005
• Sales By Destination, 2005
• Sales By Origin, 2005
• Breakdown Of Organon Sales By Destination, 2005
• Sales of Current Top Products (2000A-2010E)
• Top Selling Products, 2005
• Breakdown Of Organon Sales By Product, 2005
• Implanon Sales (2000A-2010E)
• NuvaRing Sales (2000A-2010E)
• Puregon/Follistim Sales (2000A-2010E)
• Livial Sales (2000A-2010E)
• Remeron Sales (2000A-2010E)
• Sales, Costs and Operating Income
• Profitability and Research Ratios
• R&D Expenditure and Capital Expenditure
• Current Assets, Liabilities and Ratio
• Assets, Cash and Liquidity
• Employees and Productivity